GoAI
Get started
Inspire Medical Systems, Inc. logo

Inspire Medical Systems, Inc.

INSP

NYSEHealthcareMedical - Devices

Open in GoAI

Regular session

$61.26

−$1.10 · -1.76%

Aug 24, 1:39 PM ET

INSP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

97

Deep Value

Momentum

41

Neutral

Sentiment

69

Bullish

Risk resilience

49

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Timothy Herbert
Listed since
May 3, 2018
Employees
1,333

Market position

Day range

Current $61.26

52-week range

Current $61.26

Open
$62.08
Previous close
$62.36
Volume
126.4K
0.12× average
Average volume
1.03M
Average daily volume
Market cap
1.77B USD
Beta
0.67
Market reference 1
50-day average
$51.0456
+20.01% above average
200-day average
$67.3851
-9.09% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.64B USD
P/E (TTM)
13.14×
P/B (TTM)
2.14×
P/S (TTM)
1.97×
EV / EBITDA
33.04×
Earnings yield
5.37%
Free cash flow yield
2.90%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
86.13%
Operating margin
6.02%
Net margin
15.03%
Return on equity
18.62%
Return on assets
16.03%
Return on invested capital
6.26%

Financial health

Debt / equity
0.04×
Current ratio
6.08×
Altman Z-score
12.44
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends96%55%13%-28%Gross margin, FY2021: 85.74%Gross margin, FY2022: 83.79%Gross margin, FY2023: 84.54%Gross margin, FY2024: 84.68%Gross margin, FY2025: 85.39%Operating margin, FY2021: -17.07%Operating margin, FY2022: -11.67%Operating margin, FY2023: -6.45%Operating margin, FY2024: 4.49%Operating margin, FY2025: 5.59%Net margin, FY2021: -18.01%Net margin, FY2022: -11.00%Net margin, FY2023: -3.39%Net margin, FY2024: 6.67%Net margin, FY2025: 15.95%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 85.74%. Gross margin FY2022 83.79%. Gross margin FY2023 84.54%. Gross margin FY2024 84.68%. Gross margin FY2025 85.39%. Operating margin FY2021 -17.07%. Operating margin FY2022 -11.67%. Operating margin FY2023 -6.45%. Operating margin FY2024 4.49%. Operating margin FY2025 5.59%. Net margin FY2021 -18.01%. Net margin FY2022 -11.00%. Net margin FY2023 -3.39%. Net margin FY2024 6.67%. Net margin FY2025 15.95%.

Income trends

Revenue

911.98M USD+13.60%

Operating income

50.95M USD+41.21%

Net income

145.42M USD+171.77%
Income trends across reported periods1.01B USD624.11M USD240.28M USD−143.55M USDRevenue, FY2021: 233.39M USDRevenue, FY2022: 407.86M USDRevenue, FY2023: 624.8M USDRevenue, FY2024: 802.8M USDRevenue, FY2025: 911.98M USDOperating income, FY2021: −39.85M USDOperating income, FY2022: −47.59M USDOperating income, FY2023: −40.27M USDOperating income, FY2024: 36.08M USDOperating income, FY2025: 50.95M USDNet income, FY2021: −42.04M USDNet income, FY2022: −44.88M USDNet income, FY2023: −21.15M USDNet income, FY2024: 53.51M USDNet income, FY2025: 145.42M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 233.39M USD. Revenue FY2022 407.86M USD. Revenue FY2023 624.8M USD. Revenue FY2024 802.8M USD. Revenue FY2025 911.98M USD. Operating income FY2021 −39.85M USD. Operating income FY2022 −47.59M USD. Operating income FY2023 −40.27M USD. Operating income FY2024 36.08M USD. Operating income FY2025 50.95M USD. Net income FY2021 −42.04M USD. Net income FY2022 −44.88M USD. Net income FY2023 −21.15M USD. Net income FY2024 53.51M USD. Net income FY2025 145.42M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue911.98M USD802.8M USD624.8M USD407.86M USD233.39M USD
Cost of goods sold133.23M USD122.99M USD96.58M USD66.12M USD33.28M USD
Gross profit778.76M USD679.82M USD528.22M USD341.74M USD200.12M USD
Research and development103.17M USD114.13M USD116.54M USD68.65M USD37.35M USD
Selling, general, and administrative624.64M USD529.61M USD451.96M USD320.69M USD202.62M USD
Operating expenses727.8M USD643.74M USD568.49M USD389.33M USD239.97M USD
Interest income17.54M USD23.25M USD20.56M USD5.05M USD125K USD
Interest expense137K USD22K USD—1.68M USD2.13M USD
Depreciation and amortization13.96M USD6.55M USD2.85M USD1.86M USD1.22M USD
Operating income50.95M USD36.08M USD−40.27M USD−47.59M USD−39.85M USD
Net income145.42M USD53.51M USD−21.15M USD−44.88M USD−42.04M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+250.96%
11 comparable reports
Latest EPS result
0.14
Estimate -0.24 · Beat by 159.34%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.81.060.32-0.43Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 10, 2025: actual 1.15, estimate 0.74, surprise +55.41%, Beat. Q2 2025, reported May 5, 2025: actual 0.1, estimate -0.23, surprise +143.48%, Beat. Q3 2025, reported Aug 4, 2025: actual 0.45, estimate 0.22, surprise +104.55%, Beat. Q4 2025, reported Nov 3, 2025: actual 0.38, estimate -0.15, surprise +353.33%, Beat. Q1 2026, reported Feb 11, 2026: actual 1.65, estimate 0.69, surprise +139.13%, Beat. Q2 2026, reported May 4, 2026: actual 0.1, estimate -0.275, surprise +136.32%, Beat. Q3 2026, reported Aug 3, 2026: actual 0.14, estimate -0.236, surprise +159.34%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 0.11, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates279.84M247.88M215.92M183.96MQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 10, 2025: actual 239.72M USD, estimate 239.76M USD, surprise -0.02%, Miss. Q2 2025, reported May 5, 2025: actual 201.32M USD, estimate 227.7M USD, surprise -11.59%, Miss. Q3 2025, reported Aug 4, 2025: actual 217.09M USD, estimate 214.5M USD, surprise +1.21%, Beat. Q4 2025, reported Nov 3, 2025: actual 224.5M USD, estimate 262.3M USD, surprise -14.41%, Miss. Q1 2026, reported Feb 11, 2026: actual 269.08M USD, estimate 265.69M USD, surprise +1.28%, Beat. Q2 2026, reported May 4, 2026: actual 204.58M USD, estimate 200.04M USD, surprise +2.27%, Beat. Q3 2026, reported Aug 3, 2026: actual 200.58M USD, estimate 194.72M USD, surprise +3.01%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 204.16M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$60.30

1.57% downside
Past 12 months12-month forecastHigh $85.00Average $60.30Low $39.00

Rating distribution

27 ratings
Strong buy00%
Buy1141%
Hold1659%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions

INSP news

defenseworld.net

Deutsche Bank AG Makes New $7.86 Million Investment in Inspire Medical Systems, Inc. $INSP

Deutsche Bank AG purchased a new stake in shares of Inspire Medical Systems, Inc. (NYSE: INSP) during the undefined quarter, according to the company in its most recent filing with the SEC. The fund purchased 176,200…

Read source
zacks.com

INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?

Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.

Read source
zacks.com

Here's Why You Should Add INSP Stock to Your Portfolio Now

Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.

Read source
defenseworld.net

Contrasting Medacta Group (OTCMKTS:MEDGF) & Inspire Medical Systems (NYSE:INSP)

Medacta Group (OTCMKTS:MEDGF - Get Free Report) and Inspire Medical Systems (NYSE: INSP - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the…

Read source
zacks.com

New Strong Buy Stocks for August 18th

ALGT, HMC, INSP, AII and ALL have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2026.

Read source
defenseworld.net

Assenagon Asset Management S.A. Increases Holdings in Inspire Medical Systems, Inc. $INSP

Assenagon Asset Management S.A. increased its position in Inspire Medical Systems, Inc. (NYSE: INSP) by 66.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and…

Read source

Corporate actions

Corporate action history

Dividend

Ex-dividend Jan 9, 2008

$9.00

Irregular

INSP peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,243.53

-0.95%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$273.71

+1.28%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.21

+0.09%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$150.62

-1.27%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$397.98

+2.02%

Novartis AG logo

NVS

Novartis AG

$158.1

-0.48%

ETFs holding INSP

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
91.33M
Weight
0.08%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$146.48-0.57%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
45.9M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.87-0.36%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
45.82M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$297.58-0.79%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
33.32M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$302.25-0.82%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
19.22M
Weight
0.04%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$353.93-1.32%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
15.2M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.1-0.99%
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
15.17M
Weight
0.09%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$56.955-0.57%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
14.45M
Weight
0.10%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$382.76-1.19%

Continue in GoAI

Research INSP

research.disclaimer